Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CDG IIx with unusual phenotype.

D Cheillan1, S Cognat, C Dorche

  • 1Service de Biochimie Pédiatrique, Hôpital Debrousse, Lyon, France. david.cheillan@chu-lyon.fr

Journal of Inherited Metabolic Disease
|April 7, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gut commensal Bacteroides faecichinchillae, a potential novel candidate of next-generation probiotics targeting type 2 diabetes.

Beneficial microbes·2026
Same author

CDG due to Defective Membrane Transporters: Update.

Journal of inherited metabolic disease·2026
Same author

Deletion of <i>C2orf34</i>, <i>PREPL</i> and <i>SLC3A1</i> causes atypical hypotonia-cystinuria syndrome.

BMJ case reports·2025
Same author

From Burden to Empowerment. Patient-Reported Influencing Factors on Participation in Shared Decision Making in Oncology, a Meta-Study.

Psycho-oncology·2025
Same author

Shared challenges and opportunities: Uncovering common ground in patient participation across different healthcare settings and patient groups. A qualitative meta-summary on patient-reported barriers and facilitators to participation in shared decision-making.

Patient education and counseling·2024
Same author

Patient reported outcomes for phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG): listening to what matters for the patients and health professionals.

Orphanet journal of rare diseases·2022
Same journal

Biallelic Loss-Of-Function Variant in ATP5ME Is Associated With Severe and Early Onset Oxidative Phosphorylation Deficiency.

Journal of inherited metabolic disease·2026
Same journal

Beyond Upper Airway Involvement: Evidence of Intrinsic Lung Disease in a Mouse Model of Mucopolysaccharidosis I.

Journal of inherited metabolic disease·2026
Same journal

Immune Dysregulation in Branched Chain Organic Acidemias.

Journal of inherited metabolic disease·2026
Same journal

Long Term Follow-Up After Transplantation in Propionic Acidemia: A Retrospective French Pediatric and Adult Cohort Study.

Journal of inherited metabolic disease·2026
Same journal

Tri-Parametric Assessment of α-Galactosidase A Activity, lysoGb3 and X-Inactivation Aids Genotype-Phenotype Categorization of Fabry Disease Female Patients.

Journal of inherited metabolic disease·2026
Same journal

Mapping the Severity of Phenylalanine Hydroxylase Deficiency.

Journal of inherited metabolic disease·2026
See all related articles

Congenital disorders of glycosylation (CDG) are genetic diseases affecting protein glycosylation. This study details a patient with CDG type IIx presenting an uncommon clinical presentation.

Area of Science:

  • Biochemistry
  • Genetics
  • Molecular Biology

Background:

  • Congenital disorders of glycosylation (CDG) encompass genetic diseases stemming from impaired protein glycosylation.
  • Defects in N-glycosylation are categorized into two main groups: Group I and Group II.
  • Group II CDG involves abnormalities in the Golgi apparatus's processing of protein-bound glycans.

Observation:

  • A patient diagnosed with CDG type IIx was identified.
  • This patient exhibited an unusual and atypical phenotype.

Findings:

  • The patient's condition represents a rare manifestation within the CDG II spectrum.
  • Detailed characterization of this unique phenotype is crucial for understanding CDG IIx.

Implications:

Related Experiment Videos

  • This case expands the known phenotypic spectrum of CDG II.
  • Further research into CDG IIx may reveal novel insights into glycosylation pathways.
  • Identifying unusual CDG phenotypes aids in diagnostic refinement and therapeutic strategies.